Floatz logo

121 assets in Urinary Bladder Carcinoma

Therapeutic assets addressing Urinary Bladder Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Visugromab
Urinary Bladder Carcinoma
CatalYm GmbHP2CCC (51)
Tinengotinib
Urinary Bladder Carcinoma
TransThera Sciences (Nanjing), Inc.P1/2CCC (50)
Copanlisib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (49)
Polio Vaccine
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (49)
Fludarabine
Urinary Bladder Carcinoma
Beijing BiotechP1/2CCC (48)
[111in]-fpi-1967
Urinary Bladder Carcinoma
Fusion Pharmaceuticals Inc.P1/2CC (47)
[225Ac]-FPI-1966
Urinary Bladder Carcinoma
Fusion Pharmaceuticals Inc.P1/2CC (47)
Vofatamab
Urinary Bladder Carcinoma
Fusion Pharmaceuticals Inc.P1/2CC (47)
e-602
Urinary Bladder Carcinoma
Palleon Pharmaceuticals, Inc.P1/2CC (46)
Camizestrant
Urinary Bladder Carcinoma
AstraZenecaP1/2CC (43)
Cik Cells
Urinary Bladder Carcinoma
Institute of Biophysics and Cell Engineering of National Academy of Sciences of BelarusP1/2CC (43)
cp-383
Urinary Bladder Carcinoma
Tasca TherapeuticsP1/2CC (43)
Datopotamab Deruxtecan
Urinary Bladder Carcinoma
AstraZenecaP1/2CC (43)
Ebnk-001
Urinary Bladder Carcinoma
Essen BiotechP1/2CC (43)
Efineptakin Alfa
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P1CC (43)
Eribulin Monomethanesulfonate
Urinary Bladder Carcinoma
Eisai Inc.P1/2CC (43)
Fapi-46
Urinary Bladder Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)
Gamma1 Heavy Chain Humanized (1-450) [Vh (Homo Sapiens Ighv4-31*01 (89.9%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo Sapiens Ighg1*01 (100%), G1M17,1 Ch1 K120, D12, L14 (Ch1 K120 (217) (121-218), Hinge 1-15 (219-233), Ch2 (234-343), Ch3 D12 (359), L14 (361) (344-448), Chs (449-450)) (121-450)], (223-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (85.3%)-Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (229-229'':232-232'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1,Glycoform Alfa
Urinary Bladder Carcinoma
Cancer Research UKP1/2CC (43)
Interleukin-15
Urinary Bladder Carcinoma
Essen BiotechP1/2CC (43)
Intismeran Autogene
Urinary Bladder Carcinoma
Merck Sharp & Dohme LLCP1/2CC (43)
Mdna11
Urinary Bladder Carcinoma
Medicenna Therapeutics, Inc.P1/2CC (43)
Modified Vaccinia Virus Ankara Vaccine Expressing P53
Urinary Bladder Carcinoma
City of Hope Medical CenterP1CC (43)
Saruparib
Urinary Bladder Carcinoma
AstraZenecaP1/2CC (43)
SL-28
Urinary Bladder Carcinoma
Second Life TherapeuticsP1/2CC (43)
Solnerstotug
Urinary Bladder Carcinoma
Sensei Biotherapeutics, Inc.P1/2CC (43)
Tarlatamab
Urinary Bladder Carcinoma
University of ArizonaP1/2CC (43)
T-Dxd
Urinary Bladder Carcinoma
AstraZenecaP1/2CC (43)
Tyra-300
Urinary Bladder Carcinoma
Tyra Biosciences, IncP1/2CC (43)
Zimberelimab
Urinary Bladder Carcinoma
Arcus Biosciences, Inc.P1CC (42)
[68ga]ga-dwj155
Urinary Bladder Carcinoma
Novartis PharmaceuticalsP1C (39)
[68ga]psma
Urinary Bladder Carcinoma
Memorial Sloan Kettering Cancer CenterP1C (39)
89zr-dfo-n-suc-c9scfv
Urinary Bladder Carcinoma
Var2 PharmaceuticalsEarly P1C (39)
89Zr-DFO-N-Suc-F8scFv
Urinary Bladder Carcinoma
Var2 PharmaceuticalsEarly P1C (39)
ab598
Urinary Bladder Carcinoma
Arcus Biosciences, Inc.P1C (39)
ai-061
Urinary Bladder Carcinoma
OncoC4, Inc.P1C (39)
bg-68501
Urinary Bladder Carcinoma
BeiGeneP1C (39)
Bgb-43395
Urinary Bladder Carcinoma
BeiGeneP1C (39)
Cadvec
Urinary Bladder Carcinoma
Baylor College of MedicineP1C (39)
Clsp-1025
Urinary Bladder Carcinoma
Clasp Therapeutics, Inc.P1C (39)
Eb-Dt-Nk-Uc101
Urinary Bladder Carcinoma
Beijing BiotechP1C (39)
Evolve104
Urinary Bladder Carcinoma
EvolveImmune United, IncP1C (39)
Fulvestrant
Urinary Bladder Carcinoma
BeiGeneP1C (39)
ide892
Urinary Bladder Carcinoma
IDEAYA BiosciencesP1C (39)
Idov-Immune
Urinary Bladder Carcinoma
ViroMissile, Inc.P1C (39)
Imiquimod
Urinary Bladder Carcinoma
Toray Industries, IncP1C (39)
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer
Urinary Bladder Carcinoma
Toray Industries, IncP1C (39)
ly4052031
Urinary Bladder Carcinoma
Eli Lilly and CompanyP1C (39)
ly4101174
Urinary Bladder Carcinoma
Eli Lilly and CompanyP1C (39)
MAT2A-IN-9
Urinary Bladder Carcinoma
IDEAYA BiosciencesP1C (39)
MGC026
Urinary Bladder Carcinoma
MacroGenicsP1C (39)
Showing 51 to 100 of 121 assets
PreviousPage 2 of 3Next